Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models

Yujing Xuan,Yuqiao Sheng,Daiqun Zhang,Kai Zhang,Zhen Zhang,Yu Ping,Shumin Wang,Xiaojuan Shi,Jingyao Lian,Kangdong Liu,Yi Zhang,Feng Li

DOI: https://doi.org/10.1016/j.tranon.2021.101138

IF: 4.803

2021-08-01

Translational Oncology

Abstract:CD276 is homogeneously overexpressed in ESCC and EAC.CD276-directed CAR-T cells demonstrate remarkable anti-tumor effects in ESCC PDX model.CD276-targeting CAR-T cells are successfully generated with patients T cells and show potent cytotoxicity against autologous tumor cells.Esophageal cancer, including esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), has a poor prognosis and limited therapeutic options. Chimeric antigen receptor (CAR)-T cells represent a potential ESCC treatment. In this study, we examined CD276 expression in healthy and esophageal tumor tissues and explored the tumoricidal potential of CD276-targeting CAR-T cells in ESCC. CD276 was strongly and homogenously expressed in ESCC and EAC tumor lesions but mildly in healthy tissues, representing a good target for CAR-T cell therapy. We generated CD276-directed CAR-T cells with a humanized antigen-recognizing domain and CD28 or 4–1BB co-stimulation. CD276-specific CAR-T cells efficiently killed ESCC tumor cells in an antigen-dependent manner both <em>in vitro</em> and <em>in vivo</em>. In patient-derived xenograft models, CAR-T cells induced tumor regression and extended mouse survival. In addition, CAR-T cells generated from patient T cells demonstrated potent cytotoxicity against autologous tumor cells. Our study indicates that CD276 is an attractive target for ESCC therapy, and CD276-targeting CAR-T cells are worth testing in ESCC clinical trials.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the efficacy and safety of CD276 as a potential target for chimeric antigen receptor T - cell (CAR - T - cell) therapy in esophageal squamous cell carcinoma (ESCC). Specifically, the research aims to:

1. **Evaluate the expression of CD276 in esophageal cancer**: Through immunohistochemistry (IHC) and public database analysis, study the expression differences of CD276 in healthy tissues and esophageal cancer tissues to determine whether it is suitable as a target for CAR - T - cell therapy.

2. **Generate and characterize CD276 - specific CAR - T - cells**: Construct CAR - T - cells carrying CD276 recognition domains and different co - stimulatory molecules (such as CD28 or 4 - 1BB), and evaluate their proliferation ability in vitro, memory differentiation ability and killing effect on tumor cells.

3. **Verify the anti - tumor effect of CAR - T - cells**: Through in vitro experiments and mouse xenograft models (including patient - derived xenograft models, PDX), evaluate the killing effect of CD276 - specific CAR - T - cells on ESCC tumor cells and their impact on the survival time of mice.

4. **Test the killing ability of CAR - T - cells against cancer stem cells**: Explore whether CD276 - specific CAR - T - cells can effectively kill cancer stem cells (CSCs) in ESCC to overcome the common drug - resistance problem in traditional treatment methods.

5. **Evaluate clinical feasibility**: Isolate T - cells from patient blood and prepare them into CAR - T - cells, and test the killing effect of these cells on autologous tumor cells to provide a basis for future clinical trials.

In summary, the main objective of this paper is to verify the feasibility and effectiveness of CD276 as a target for CAR - T - cell therapy in ESCC and lay the foundation for further research in its clinical application.